Keywords: dor, biopharma, reports, progress, rivax, vaccine, formulation

DOR BioPharma reports progress on RiVax vaccine formulation

Article | 20 November 2006

Print This

DOR BioPharma says it has made advancements in the long-term stability and optimization of the formulation of RiVax, a vaccine ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in